Lamontagne F, Richards-Belle A, Thomas K, et al. - A randomized clinical trial was designed to ascertain whether decreasing exposure to vasopressors through permissive hypotension (mean arterial pressure [MAP] target, 60-65 mm Hg) reduces mortality at 90 days in ICU patients aged 65 years or older with vasodilatory hypotension. Researchers performed a multicenter, pragmatic, randomized clinical trial in 65 ICUs in the United Kingdom including a total of 2,600 randomized individuals aged 65 years or older with vasodilatory hypotension (assessed by treating clinician) between July 2017 and March 2019, and follow-up was completed in August 2019. Individuals were assigned randomly 1:1 to vasopressors guided either by MAP target (60-65 mm Hg, permissive hypotension) (n = 1,291) or according to usual care (at the discretion of treating clinicians) (n = 1,307). The permissive hypotension in comparison with usual care did not result in a statistically significant reduction in mortality at 90 days among individuals 65 years or older receiving vasopressors for vasodilatory hypotension. Nevertheless, when interpreting the clinical importance of the study, the confidence interval around the point estimate should be considered.